MASCC/ESMO Update Guidelines for CINV Prophylaxis

Share this content:
MASCC/ESMO Update Guidelines for CINV Prophylaxis
MASCC/ESMO Update Guidelines for CINV Prophylaxis

The Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO) have issued an update to their joint recommendations for the prevention of nausea and vomiting following multiple-day chemotherapy and high-dose chemotherapy, and for breakthrough nausea and vomiting.1

Continue Reading Below

Key recommendations from the 2016 updated MASCC/ESMO consensus recommendations include:

• For patients receiving high-dose chemotherapy with hematopoietic stem cell transplantation (HSCT), a 5-HT3 receptor antagonist with dexamethasone and aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 to 4) is recommended prior to chemotherapy.

• For patients undergoing multiple-day chemotherapy-induced, a 5-HT3 receptor antagonist, dexamethasone, and aprepitant are recommended prior chemotherapy for the prevention of acute emesis and delayed emesis.

• For patients experiencing breakthrough nausea and vomiting, the available evidence suggests the use of olanzapine 10 mg orally daily for 3 days; however, mild to moderate sedation with this agent may be problematic in this patient population (especially older patients).

To formulate these updates, investigators conducted a systematic literature and identified 3 phase 3 randomized trials in patients undergoing high-dose chemotherapy and HSCT and 8 single-arm in patients undergoing HSCT and in those receiving multiple-day chemotherapy.

For patients receiving treatment for breakthrough CINV, investigators also identified a phase 3 randomized trial evaluating the use of olanzapine vs metoclopramide in patients receiving highly emetogenic chemotherapy and a single-arm study investigating the effectiveness of olanzapine.

Two randomized clinical trials were ultimately used for this guideline update.


1. Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Supp Care Cancer. 2016 Nov 4. doi: 10.1007/s00520-016-3449-y. [Epub ahead of print]

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs